{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T00:59:47Z","timestamp":1794963587091,"version":"4.9.1"},"reference-count":29,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["RAAIDD"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Since leprosy bacilli cannot grow in vitro, testing for\nantimicrobial resistance against Mycobacterium leprae or assessing the anti-leprosy\nactivity of new drugs remains hard. Furthermore, developing a new leprosy drug through\nthe traditional drug development process is not economically captivating for\npharmaceutical companies. As a result, repurposing existing drugs\/approved medications\nor their derivatives to test their anti-leprotic potency is a promising alternative. It is an\naccelerated method to uncover different medicinal and therapeutic properties in approved\ndrug molecules.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Aims:<\/jats:title>\n<jats:p>The study aims to explore the binding potential of anti-viral drugs such as\nTenofovir, Emtricitabine, and Lamivudine (TEL) against Mycobacterium leprae using\nmolecular docking.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>The current study evaluated and confirmed the possibility of repurposing antiviral\ndrugs such as TEL (Tenofovir, Emtricitabine, and Lamivudine) by transferring the\ngraphical window of the BIOVIA DS2017 with the Crystal Structure of a\nphosphoglycerate mutase gpm1 from Mycobacterium leprae (PDB ID: 4EO9). Utilizing\nthe smart minimizer algorithm, the protein's energy was reduced in order to achieve a\nstable local minima conformation.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>The protein and molecule energy minimization protocol generated stable configuration\nenergy molecules. The protein 4EO9 energy was reduced from 14264.5\nkcal\/mol to -17588.1 kcal\/mol.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>The CHARMm algorithm-based CDOCKER run docked all three molecules\n(TEL) inside the 4EO9 protein binding pocket (Mycobacterium leprae). The interaction\nanalysis revealed that tenofovir had a better binding molecule with a score of -\n37.7297 kcal\/mol than the other molecules.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/2772434418666230220123217","type":"journal-article","created":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T10:56:54Z","timestamp":1676890614000},"page":"170-177","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A Perspective into \u201cTEL\u201d-Tenofovir, Emtricitabine and Lamivudine\nAntileprotic Activities by Drug Repurposing and Exploring\nthe Possibility of Combination Chemotherapy with Drug Rescued\nMolecules for a Leprosy Free Mankind"],"prefix":"10.2174","volume":"18","author":[{"given":"Pugazhenthan","family":"Thangaraju","sequence":"first","affiliation":[{"name":"Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Raipur, Chhattisgarh,\n492099, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sree Sudha Tanguturi","family":"Yella","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, All India Institute of Medical Sciences, Deoghar,\nIndia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijayakumar Arumugam","family":"Ramamurthy","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Pharmacy, Sree Balaji Medical College\nand Hospital, Biher, Chennai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irfan","family":"Navabshan","sequence":"additional","affiliation":[{"name":"School of Pharmacy, B.S. Abdur Rahman Crescent Institute of\nScience &amp; Technology, Vandalur, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thameemul Ansari Lappathai Habeeb","family":"Mohamed","sequence":"additional","affiliation":[{"name":"School of Pharmacy, B.S. Abdur Rahman Crescent Institute of\nScience &amp; Technology, Vandalur, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S0140-6736(64)92482-1","volume":"284","author":"Pettit J.H.S.","year":"1964","unstructured":"Pettit J.H.S.; Rees R.J.W.; Sulphone resistance in leprosy. An experimental and clinical study. Lancet 1964,284(7361),673-674","journal-title":"Lancet"},{"key":"ref=2","first-page":"131","volume":"81","author":"Gupta U.D.","year":"2009","unstructured":"Gupta U.D.; Katoch K.; Katoch V.M.; Study of rifampicin resistance and comparison of dapsone resistance of M. leprae in pre- and post-MDT era. Indian J Lepr 2009,81(3),131-134","journal-title":"Indian J Lepr"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1136\/bmj.39500.885752.BE","volume":"336","author":"Moet F.J.","year":"2008","unstructured":"Moet F.J.; Pahan D.; Oskam L.; Richardus J.H.; Effectiveness of single dose rifampicin in preventing leprosy in close contacts of patients with newly diagnosed leprosy: Cluster randomised controlled trial. BMJ 2008,336(7647),761-764","journal-title":"BMJ"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/S0140-6736(76)92071-7","volume":"2","author":"Jacobson R.R.","year":"1976","unstructured":"Jacobson R.R.; Hastings R.C.; Rifampin-resistant leprosy. Lancet 1976,2(7998),1304-1305","journal-title":"Lancet"},{"key":"ref=5","first-page":"2","volume":"44","author":"Noordeen S.K.","year":"1991","unstructured":"Noordeen S.K.; Lopez Bravo L.; Daumerie D.; Global review of multidrug therapy (MDT) in leprosy. World Health Stat Q 1991,44(1),2-15","journal-title":"World Health Stat Q"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0140-6736(05)60888-4","volume":"349","author":"Cambau E.","year":"1997","unstructured":"Cambau E.; Perani E.; Guillemin I.; Jamet P.; Ji B.; Multidrug-resistance to dapsone, rifampicin, and ofloxacin in Mycobacterium leprae. Lancet 1997,349(9045),103-104","journal-title":"Lancet"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1128\/CMR.19.2.338-381.2006","volume":"19","author":"Scollard D.M.","year":"2006","unstructured":"Scollard D.M.; Adams L.B.; Gillis T.P.; Krahenbuhl J.L.; Truman R.W.; Williams D.L.; The continuing challenges of leprosy. Clin Microbiol Rev 2006,19(2),338-381","journal-title":"Clin Microbiol Rev"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"e1008341","DOI":"10.1371\/journal.ppat.1008341","volume":"16","author":"Huang F.","year":"2020","unstructured":"Huang F.; Zhang C.; Liu Q.; Identification of amitriptyline HCl, flavin adenine dinucleotide, azacitidine and calcitriol as repurposing drugs for influenza A H5N1 virus-induced lung injury. PLoS Pathog 2020,16(3),e1008341","journal-title":"PLoS Pathog"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.therap.2020.02.007","volume":"75","author":"Scherman D.","year":"2020","unstructured":"Scherman D.; Fetro C.; Drug repositioning for rare diseases: Knowledge-based success stories. Therapie 2020,75(2),161-167","journal-title":"Therapie"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.2174\/1386207325666211007110638","volume":"25","author":"Sharma M.","year":"2022","unstructured":"Sharma M.; Singh P.; Repurposing drugs to combat drug resistance in leprosy: A review of opportunities. Comb Chem High Throughput Screen 2022,25(10),1578-1586","journal-title":"Comb Chem High Throughput Screen"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"23629","DOI":"10.1039\/C8RA01854E","volume":"8","author":"Balasubramaniyan S.","year":"2018","unstructured":"Balasubramaniyan S.; Irfan N.; Umamaheswari A.; Puratchikody A.; Design and virtual screening of novel fluoroquinolone analogs as effective mutant DNA GyrA inhibitors against urinary tract infection-causing fluoroquinolone resistant Escherichia coli. RSC Advances 2018,8(42),23629-23647","journal-title":"RSC Advances"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1007\/s12033-021-00358-z","volume":"63","author":"Navabshan I.","year":"2021","unstructured":"Navabshan I.; Sakthivel B.; Pandiyan R.; Computational lock and key and dynamic trajectory analysis of natural biophors against COVID-19 spike protein to identify effective lead molecules. Mol Biotechnol 2021,63(10),898-908","journal-title":"Mol Biotechnol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"58","DOI":"10.4103\/ijcm.IJCM_155_17","volume":"43","author":"Thangaraju P.","year":"2018","unstructured":"Thangaraju P.; Venkatesan S.; Showkath Ali M.K.; Final leprosy push: Out of society. Indian J Community Med 2018,43(1),58-59","journal-title":"Indian J Community Med"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1093\/cid\/ciz570","volume":"70","author":"Rosa P.S.","year":"2020","unstructured":"Rosa P.S.; D\u2019Espindula H.R.S.; Melo A.C.L.; Emergence and transmission of drug\/multidrug-resistant Mycobacterium leprae in a former leprosy colony in the Brazilian Amazon. Clin Infect Dis 2020,70(10),2054-2061","journal-title":"Clin Infect Dis"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.clindermatol.2015.10.019","volume":"34","author":"Saunderson P.R.","year":"2016","unstructured":"Saunderson P.R.; Drug-resistant M. leprae. Clin Dermatol 2016,34(1),79-81","journal-title":"Clin Dermatol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"547","DOI":"10.4269\/ajtmh.19-0390","volume":"102","author":"Mahajan N.P.","year":"2020","unstructured":"Mahajan N.P.; Lavania M.; Singh I.; Evidence for Mycobacterium leprae drug resistance in a large cohort of leprous neuropathy patients from India. Am J Trop Med Hyg 2020,102(3),547-552","journal-title":"Am J Trop Med Hyg"},{"key":"ref=17","year":"1998","unstructured":"WHO Expert Committee on Leprosy: Seventh report 1998","journal-title":"Seventh report"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/ijdd.ijdd_66_19","volume":"6","author":"Pai V.","year":"2020","unstructured":"Pai V.; Second-line anti-leprosy drugs: Indian experience. Indian J Dermatol 2020,6(1),1","journal-title":"Indian J Dermatol"},{"key":"ref=19","first-page":"S14","volume":"69","author":"Grosset J.H.","year":"2001","unstructured":"Grosset J.H.; Newer drugs in leprosy. Int J Lepr Other Mycobact Dis 2001,69(2),S14-S18","journal-title":"Int J Lepr Other Mycobact Dis"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1128\/AAC.37.2.332","volume":"37","author":"Balzarini J.","year":"1993","unstructured":"Balzarini J.; Holy A.; Jindrich J.; Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine. Antimicrob Agents Chemother 1993,37(2),332-338","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1126\/science.270.5239.1197","volume":"270","author":"Tsai C.C.","year":"1995","unstructured":"Tsai C.C.; Follis K.E.; Sabo A.; Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science 1995,270(5239),1197-1199","journal-title":"Science"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1093\/cid\/ciu729","volume":"42","author":"Saag M.S.","year":"2006","unstructured":"Saag M.S.; Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus. Clin Infect Dis 2006,42(1),126-131","journal-title":"Clin Infect Dis"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1080\/14656566.2020.1713096","volume":"21","author":"Mu Y.","year":"2020","unstructured":"Mu Y.; Pham M.; Podany A.T.; Cory T.J.; Evaluating emtricitabine + rilpivirine + tenofovir alafenamide in combination for the treatment of HIV-infection. Expert Opin Pharmacother 2020,21(4),389-397","journal-title":"Expert Opin Pharmacother"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"100028","DOI":"10.1016\/j.jve.2021.100028","volume":"7","author":"Waters L.","year":"2021","unstructured":"Waters L.; Mehta V.; Gogtay J.; Boffito M.; The evidence for using tenofovir disoproxil fumarate plus lamivudine as a nucleoside analogue backbone for the treatment of HIV. J Virus Erad 2021,7(1),100028","journal-title":"J Virus Erad"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1177\/1060028020933772","volume":"54","author":"Santevecchi B.A.","year":"2020","unstructured":"Santevecchi B.A.; Miller S.; Childs-Kean L.M.; Doing more with less: Review of dolutegravir-lamivudine, a novel single-tablet regimen for antiretroviral-Na\u00efve adults with HIV-1 infection. Ann Pharmacother 2020,54(12),1252-1259","journal-title":"Ann Pharmacother"},{"key":"ref=26","first-page":"8","volume":"27","author":"Buchbinder S.P.","year":"2019","unstructured":"Buchbinder S.P.; Liu A.Y.; CROI 2019: Advances in HIV prevention and plans to end the epidemic. Top Antivir Med 2019,27(1),8-25","journal-title":"Top Antivir Med"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/nrmicro975","volume":"2","author":"Clercq E.D.","year":"2004","unstructured":"Clercq E.D.; Antivirals and antiviral strategies. Nat Rev Microbiol 2004,2(9),704-720","journal-title":"Nat Rev Microbiol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13027-021-00359-2","volume":"16","author":"Zhang S.","year":"2021","unstructured":"Zhang S.; Li N.; Sheng Y.; Hepatitis B virus induces sorafenib resistance in liver cancer via upregulation of cIAP2 expression. Infect Agent Cancer 2021,16(1),20","journal-title":"Infect Agent Cancer"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"100152","DOI":"10.1016\/j.jhepr.2020.100152","volume":"2","author":"Hui V.W.K.","year":"2020","unstructured":"Hui V.W.K.; Chan S.L.; Wong V.W.S.; Increasing antiviral treatment uptake improves survival in patients with HBV-related HCC. JHEP Reports 2020,2(6),100152","journal-title":"JHEP Reports"}],"container-title":["Recent Advances in Anti-Infective Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/2772434418666230220123217","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/213812\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/2772434418666230220123217","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T07:44:04Z","timestamp":1690184644000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/213812\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/2772434418666230220123217","relation":{},"ISSN":["2772-4344"],"issn-type":[{"value":"2772-4344","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-08-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-03","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}